Related Experiment Video

Updated: Jun 2, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer

Menno T De Bruijn1, Daniëlle A E Raats, Jolien Tol

  • 1Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.

Anticancer Research
|April 22, 2011
PubMed
Abstract

Insights

The combined mutation status of Kirsten ras (KRAS) and tumour suppressor p53 (TP53) genes does not predict chemotherapy response in metastatic colorectal cancer patients. This finding impacts personalized treatment strategies for colorectal tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) treatment response varies significantly.
  • Preclinical studies suggest KRAS and TP53 mutations influence CRC cell sensitivity to oxaliplatin and capecitabine.
  • Investigating combined KRAS and TP53 mutation status as a predictive biomarker for CRC chemotherapy response is crucial.

Purpose of the Study:

  • To determine if combined KRAS and TP53 mutation status predicts treatment response in metastatic colorectal cancer patients receiving CAPOX plus bevacizumab.
  • To analyze the association between KRAS/TP53 genotypes and patient outcomes in the CAIRO2 trial.

Main Methods:

  • Analysis of a subgroup of patients from the CAIRO2 phase III clinical trial.
  • Tumor samples were genotyped for KRAS and TP53 mutations using PCR/sequencing.
  • Correlation between specific genotypes (KRASmut/TP53mut, KRASmut/TP53wt, KRASwt/TP53mut, KRASwt/TP53wt) and treatment response was assessed.

Main Results:

  • Four distinct KRAS/TP53 genotype groups were identified with varying frequencies.
  • No statistically significant association was found between any KRAS/TP53 genotype and progression-free or overall survival.
  • The combined mutation status of KRAS and TP53 did not serve as a predictive biomarker for CAPOX treatment efficacy.

Conclusions:

  • Combined KRAS and TP53 mutation status is not a reliable predictor of response to capecitabine, oxaliplatin, and bevacizumab chemotherapy in metastatic colorectal cancer.
  • These findings suggest alternative biomarkers may be needed to guide treatment decisions for CRC patients.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...